Background Basic and clinical research support the hypothesis that activation of the coagulation and inflammation pathways may affect cancer onset, but there is limited epidemiological data to support this.
Introduction
Circulating levels of inflammation markers have been linked to the pathogenesis of several cancers [1] [2] [3] and there is growing interest on the possible role of circulating levels of haemostatic variables. Cancer is diagnosed more often after an episode of venous thromboembolism. 4, 5 Two relatively small follow-up studies have reported positive associations between circulating levels of fibrinogen and subsequent cancer mortality. 6, 7 The role of haemostatic variables on the pathogenesis of cancer is also supported by studies showing that anticoagulation may have an anti-tumour effect in addition to its antithrombotic effect. Aspirin and other non-steroidal anti-inflammatory drugs reduce the risk of colorectal cancer 8 and warfarin use has been found to be associated with a decreased risk of urogenital cancers, 9 mainly prostate cancer. 10 The aim of this study was to examine the role of a large range of coagulation and inflammation markers on cancer incidence in three English cohorts comprising almost 20 000 male participants followed for up to 30 years.
Methods

Study subjects
We have access to data from three long-term cohort studies: the first and second Northwick Park Heart Study (NPHS-I and NPHS-II) and the Thrombosis Prevention Trial (TPT). They were coordinated by the same research group, using generally similar methods for obtaining and processing blood samples.
NPHS-I was the first systematic epidemiological investigation of the contribution of the haemostatic system to the thrombotic component of coronary heart disease (CHD). 11 It recruited 2167 White men aged 418 years (80% of those eligible) between 1972 and 1978 by invitation to factory and office workers in three North West London occupational groups. NPHS-II extended the aims of NPHS-I by including several new assays for clotting factor activity and indices of thrombin production and activity, 12 none of which was available when NPHS-I was conducted. It began in 1989 and recruited 3052 men aged 50-61 years (76% of those eligible) who were registered in nine general practices in England and Scotland and had no history of cardiovascular disease or cancer. Of these, more than 700 were resident in Scotland and were excluded from this analysis because of incomplete follow-up. TPT, a double-blind factorial randomized controlled trial of low-intensity anticoagulation with warfarin and low-dose aspirin initiated in 1989, 13, 14 recruited men aged 45-69 years and at high risk of CHD but without a history of clinical episodes. Our analysis includes baseline data from the 5057 men at high CHD risk who did not take part in the treatment phase of the trial ('high-risk' group) and a sample of 12 159 men found to be at lower risk during the trial's screening phase ('low-risk group'). The 5499 men at 'high risk' enrolled into the trial were excluded from this analysis because treatment could have affected cancer incidence.
Entry variables
Together, these three studies collected data on a large range of inflammation and haemostatic variables (Table 1 ) based on non-fasting blood samples taken at entry (or at screening in TPT). Fibrinogen was measured by clot weight in NPHS-I and the von Clauss thrombin clotting time method in NPHS-II and TPT. Fibrinolytic activity (FA) was assessed by the time to dissolution of clot (expressed as 100/lysis time in hours). Prothrombin fragment F1.2 was measured by double-antibody radioimmunoassay and fibrinopeptide A (FPA) by commercial radioimmunoassay (Byk-Sangtec, Dietzenbach, Germany) as indices of thrombin production and activity, respectively. Factors VII and VIII were measured as described in Meade et al. 11 and VIIa, XIIa, Protein S and C-reactive protein (CRP) as described in Cooper et al.
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Haematological variables were measured by automated Coulter counts and serum cholesterol by an automated procedure (Sigma, Poole, Dorset, UK).
Blood pressure measurements were recorded by a random-zero sphygmomanometer and anthropometric variables measured using standard methods. Data on several potential confounders and effect modifiers were collected by questionnaire at the time of entry (or screening in TPT) ( Table 1) . Social class was ascertained according to the occupation held at the time of recruitment. 15 Entry smoking status was categorized as never-/ex-/current smoker in NPHS-I and NPHS-II, and as current (yes/no) in TPT. Life-time amount smoked up to the time of entry was estimated as pack-years (i.e. number of cigarettes, or equivalent units for pipes and cigars, per day multiplied by number of years smoked divided by 20) in NPHS-I and NPHS-II. Current alcohol intake at entry was defined as consumption of at least one alcoholic drink in the week prior to entry/screening, with weekly amount for NPHS-I and NPHS-II estimated from number of drinks per week, and expressed as numbers of equivalent glasses of wine.
Follow-up variables
In NPHS-I, all haemostatic variables were remeasured in 65% of participants 6 years after entry, on average, whereas in NPHS-II fibrinogen and factors VII and XIIa were measured five times at yearly intervals but, to ensure comparability with NPHS-I, only the 5-year follow-up measures were included in these analyses. These repeat measurements were used to define single-occasion (i.e. either entry or follow-up) and persistently (i.e. both entry and follow-up) raised Median and interquartile range are shown. c Refers to the 'not current smokers' category, as assessed at entry into the study. b n: number of participants with complete data on exposure and potential confounder(s); d ¼ number of incident cancer cases. All cancers (ICD-10): C00-C94.3, C94.6-C99.9, D00-D48.9; smoking-related cancers: C010-069, C090-109, C120-149, C150-159, C160-169, C250-259, C320-329, C330-349, C384, C450-459, C670-689; lung cancer: C330-349, C384, C450-459; digestive cancers: C150-159, C160-169, C170-179, C180-219, C220-249, C250-259, C260-269, C480-489; colorectal cancer: C180-219; male genital cancers: C600-609, C610-619, C620-C629, C630-639; haematological cancers: C810-819, C820-859, C880-889, C900-902, C914, C960-963, C967, C969. c P t : P-value of test for linear trend across fourths; P l : P-value of test for departure from linearity.
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(44 g/l) fibrinogen levels. A cut-off point of 3.5 g/l was also used. Follow-up questionnaire data on smoking status and quantity, available in both NPHS-I and NPHS-II, were used to define cumulative amount smoked up to the follow-up visit.
Outcome ascertainment Site-specific cancer incidence, cause-specific mortality and loss-to-follow-up for the three cohorts were ascertained through the England & Wales National Health Services Central Register (NHSCR) with independent assessment from general practices, hospital records, and coroners. Events were coded according to the International Classification of Diseases (ICD), 16 with appropriate bridging across ICD revisions.
Statistical analysis
For each study, follow-up time was calculated from the beginning of the fourth year since entry up to the occurrence of the earliest event of: cancer incidence, death, emigration, 90th birthday or 30 June 2006. The first 3 follow-up years were excluded to minimize the potential for any effects of incipient cancer on the exposures of interest.
Analyses were carried out separately by study (and for TPT also separately by risk group) and then jointly, if appropriate. Circulating levels of fibrinogen and other haemostatic and inflammation variables, when available, were related to incidence of cancer. Analyses were based on the competing risks model proposed by Fine and Gray 17 because of the expected correlations among times to specific cancers as well as with time to cardiovascular death. The resulting estimates-referred to as competing incidence rate ratios (RRs)-represent the effects of the explanatory variables on (a transformation of) the cumulative incidence function (CIF). As age was the time scale of analysis all estimated RRs are age-adjusted. Further adjustment for smoking and other potential confounders was performed.
Each exposure variable was examined on both a continuous scale, in terms of effect per 1 SD increase, and a categorical scale, in study-specific fourths of the overall distribution, with RRs computed relative to the lowest fourth (reference). Departure from linearity was assessed by including quadratic terms. Effect modification was tested by including appropriate interaction terms. When assessing the potential modifying effect of smoking, interaction terms were defined both for smoking status and cumulative amount smoked, when available. P-values, including P-values of test for linearity and for effect modification, were examined via likelihood ratio tests. 18 The proportionality of effects was assessed via Schoenfeld's residuals. 19 When no evidence of between-study heterogeneity was found, RRs were pooled to produce summary estimates by fitting a random effects model to the study-specific RRs. 20 To allow for regression dilution effect in the age-adjusted estimated RRs for fibrinogen, the method of moments was used to correct the estimated RRs. 21 
Results
Baseline characteristics
After exclusions due to missed linkage to the NHSCR and to death, cancer or migration in the first 3 years of follow-up, the analyses concern 19 303 men (Table  1) . Participants in NPHS-I were, on average, 8 years younger at entry than those in NPHS-II; they were also more likely to have been current smokers but otherwise-given the age differences-were similar. Participants in TPT were of similar ages to those in NPHS-II, with the high-risk group having a higher percentage of current smokers at entry as well as elevated average values for all the clinical, biochemical and haemostatic variables examined (Table 1) . A total of 2908 cancers were accrued (Table 2 ) during a follow-up time ranging from 3.0 to 34.2 years (median: 25.6 years in NPHS-I, 11.7 in NPHS-II and 12.4 in TPT overall). Smoking-related cancers accounted for $40% of all malignancies in NHPS-I and TPT-high risk but for only $29% in the other studies.
Fibrinogen levels and cancer incidence
Continuous fibrinogen levels were positively associated with overall (all sites combined) cancer risk in each study (Table 2 ). Categorical fibrinogen also showed positive associations with all-sites cancer risk, with linear trends across the categories found in NPHS-II and TPT low risk, the two cohorts for which the magnitude of the effect on the continuous scale was strongest (Table 2) . These results were mainly due to the association of fibrinogen with smoking-related cancers [pooled age-adjusted RR (95% CI) of smoking-related cancers per 1 SD increase in fibrinogen levels: 1.23 (1.12, 1.36); Figure 1 ]. Although the magnitude of the fibrinogen effect was stronger for lung cancer (Table 2) , but with evidence of between-study heterogeneity (P ¼ 0.006; Figure 2 ), it was also present for all the other smoking-related cancers [pooled age-adjusted RR (95% CI) 1.10 (0.97, 1.26)]. Fibrinogen levels were not associated with risk of non-smoking-related cancers overall, nor with risk of digestive, genital or haematological cancers when analysed separately (Table 2 ; Supplementary Figures  1-3 ; Supplementary data are available at IJE online). Replication data on fibrinogen from NPHS-II, consisting of 267 independent repeat measures taken 6 weeks apart, were used to correct the age-adjusted estimates, leading to increased RRs by 15% for smoking-related cancers [corrected pooled age-adjusted RRs ($95% CI) per 1 SD increase in fibrinogen levels: 1.40 (1.19, 1.63)] and by $24% for the study-specific RRs for lung cancer. (Figure 1) . Similar reductions in effect were found for lung cancer (Supplementary Table 2 ; Supplementary data are available at IJE online; Figure 2 ). Further adjustment for other potential confounders only moderately reduced these estimates (Supplementary Table 2 ; Supplementary data are available at IJE online; Figures 1 and 2 ). Equivalent analyses for non-smoking-related cancers overall (Supplementary Table 2 ; Supplementary data are available at IJE online) and separately for digestive, genital and haematological cancers ( Supplementary Figures 1-3 ; Supplementary data are available at IJE online) showed no association with fibrinogen levels.
The association between fibrinogen and risk of smoking-related cancers was further examined in the separate strata of current/ex-and never-smokers at entry in NPHS-I and NPHS-II. As the RRs for these two studies were similar, estimates were derived from the combined data. The positive association between fibrinogen levels and risk of smoking-related cancers was present only among current smokers (Table 3) .
Single-occasion vs persistently raised fibrinogen levels Similar positive associations with risk of smokingrelated cancers were observed when analysing follow-up rather than baseline fibrinogen levels in the subsets of 1507 NPHS-I and 1446 NHPS-II participants with follow-up measurements taken 5-6 years after entry [combined age-smoking-adjusted RR (95% CI) for smoking-related and lung cancers per 1 SD increase in fibrinogen levels: 1.37 (1.19, 1.58) and  1.62 (1.33, 1.96) , respectively]. Persistently raised fibrinogen levels were strongly associated with increased risk of both smoking-related cancers and lung cancer [combined age-smoking-adjusted RR (95% CI): 2.61 (1.40, 4.86) and 2.99 (1.27, 7.08), respectively; Supplementary Table 3 ; Supplementary data are available at IJE online]. In contrast, single-occasion high fibrinogen level was only moderately associated with these outcomes. Among those with persistently raised levels, 61% were current smokers and 30% were ex-smokers; the corresponding figures among those with single-occasion raised levels were 36 and 34%, respectively. Similar results were obtained when 3.5 g/l was used as the cut-off point (Supplementary Table 3 ; Supplementary data are available at IJE online).
Fibrinogen as a mediator of the effect of smoking on lung cancer incidence To assess whether fibrinogen levels could mediate the association between smoking and lung cancer, we compared the effect of smoking before and after adjustment for fibrinogen levels. In NPHS-I and NPHS-II combined, the age-adjusted rates of lung cancer were approximately 15 times (combined age-adjusted RR ¼ 14.5; 95% CI 5.3, 10.3) higher in Study-specific fourths, as defined in Table 2 . c P t : P-value of test for linear trend across fourths; P l : P-value of test for departure from linearity. 
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current smokers and four times higher among ex-smokers (combined age-adjusted RR ¼ 3.5; 95% CI 1.2, 10.3) relative to never-smokers. Further adjustment for baseline fibrinogen levels reduced the smoking effects only marginally [combined agefibrinogen-adjusted RRs (95% CI) 12.7 (4.6, 34.6) and 3. 4 (1.2, 10.0) , respectively].
In the subset of 2953 NPHS-I and NPHS-II participants with follow-up data, the reduction in the magnitude of the smoking effects was slightly more marked on simultaneous adjustment for both baseline and follow-up fibrinogen levels. Relative to never-smokers the combined age-adjusted RR (95% CI) for lung cancer was 19.0 (4.6, 78.2) for current smokers and 5.1 (1.2, 22.4) for ex-smokers, relatively to never-smokers, with the magnitude of these associations declining respectively to 14.2 (3.4, 58.9) and 4.6 (1.0, 20.1), with further simultaneous adjustment for baseline and follow-up fibrinogen levels. These results would be consistent with fibrinogen being a possible mediator of the effect of smoking on lung cancer incidence.
The role of other inflammatory and haemostatic factors WBC count, available only in NPHS-I, and continuous CRP and VIIa, available only in NPHS-II, were associated with incidence of smoking-related cancers and, with the exception of VIIa, lung cancer. However, each of these associations was fully confounded by smoking (Table 4) . Prothrombin fragment F1.2, only available in NPHS-II, was associated with risk of smoking-related cancers and lung cancer even after controlling for smoking (Table 4) . Analyses restricted to never-smokers were hampered by small number of cases. No cancer associations were found with any other haemostatic or inflammation variable (Supplementary Table 4 ; Supplementary data are available at IJE online).
Discussion
The present analysis revealed positive associations between circulating levels of fibrinogen, CRP, VIIa and prothrombin fragment F1.2, and also of WBC, with subsequent risk of smoking-related cancers. Measurement error may have underestimated the magnitude of these associations, possibly by $20% for fibrinogen. Smoking was, however, a strong confounder and, with the exception of F1.2, these associations were either considerably attenuated (fibrinogen) or removed (WBC, CRP and VIIa) after adjustment for this variable. Furthermore, no associations with fibrinogen were observed among never-smokers, suggesting that smoking accounted for most of the excess risks at these cancer sites. Cigarette smoking is an important determinant of levels of fibrinogen, and other inflammation markers, and it is also a strong risk factor for many cancers. So, while we cannot exclude the possibility of a true independent association between levels of inflammatory and haemostatic variables and subsequent incidence of smoking-related cancers, residual confounding by smoking is a likely explanation for any remaining effects. Nevertheless, activation of the inflammation and coagulation cascades may still be important in the pathogenesis of smoking-related cancers, with inflammation and haemostatic factors being markers of susceptibility to the effects of smoking and/or markers of the biological effects of this exposure on cells in the target tissues. Our findings, particularly those based on both baseline and follow-up fibrinogen levels, are consistent with fibrinogen being a potential mediator of the smoking effect on the incidence of lung cancer. In contrast, the association of F1.2 with smoking-related cancer incidence was not reduced by adjustment for smoking, suggesting a thrombogenic effect via activation of the coagulation pathway, but this finding was based on data from only one study.
Previous epidemiological studies have found associations between fibrinogen levels and cancer mortality, 6, 7 mostly as in the present study, with smoking-related cancers. 6 A recent meta-analysis, focused on cardiovascular diseases, reported positive associations between fibrinogen levels and mortality from smoking-related cancers among all participants and among never-smokers only. 22 Others have examined the role of WBC count on cancer mortality, with one reporting a positive association 1 and another no association. 2 Fewer studies have examined risks in relation to cancer incidence. A US prospective study found positive associations with circulating levels of inflammation markers such as interleukin-6, CRP and tumour necrosis factor-a, but interestingly these associations were stronger for cancer mortality than for cancer incidence. 3 Similarly to our findings, a recent meta-analysis 23 found an association between CRP levels and cancer incidence, essentially driven by a positive CRP-lung cancer association. Miller et al. 24 found that persistent activation of the haemostatic pathway was associated with an elevated risk of digestive cancers. However, many of the cancers arose within a short time of recruitment into the study so that reverse causality was a real possibility. We were unable to confirm the finding in the present analysis although there was evidence in NPHS-II of a positive association between F1.2 and smokingrelated cancers. Laboratory-based research has considered pathways through which activation of the coagulation cascade might be associated with cancer, but it is unclear whether the proposed mechanisms (e.g. stimulation of tumour growth and angiogenesis; 25, 26 promotion of metastatic potential by impeding natural killer cell elimination of tumour cells; 27, 28 smoking-induced damage with oxidation and nitration of DNA and plasma proteins such as The present analysis is based on three male cohorts and, thus, its findings may not be generalizable to women. Other limitations include inadequate power to examine separately risks in relation to individual cancers, other than lung and colon-rectum, and limited data on smoking habits for the two TPT groups.
In summary, our results show that pre-diagnostic levels of coagulation and inflammatory markers, particularly fibrinogen, are associated with risk of smoking-related cancers. The aetiological significance of these findings is unclear. Residual confounding by smoking may account for most of the remaining observed effects among smokers. Alternatively, fibrinogen may be a mediator of the smoking-cancer associations, or simply a correlate of the effects of smoking on target tissues. Assessment of the aetiological significance of high fibrinogen levels in relation to cancer risks will require strategies that can minimize potential residual biases by smoking and other variables. One possible avenue would be the use of Mendelian randomization 30 to investigate potential associations between genetic determinants of circulating levels of fibrinogen (and other coagulation markers) and cancer risks in large-scale observational studies. Overview results from trials of fibrates, which lower fibrinogen levels by $15%, may also provide evidence for or against an independent effect of fibrinogen on cancer onset. A recent trial of fenofibrate reported no difference in cancer risks, but based on small number of cases, between the intervention and the placebo arms. 31 
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